This subtype was observed in 37% of patients who had KRAS mutations, which is consistent with our findings.41 KRAS mutations are typically found in approximately 40% of colorectal cancer patients (stages II–IV), and their established role as adverse predictive factors for the effectiveness of anti-EGFR therapy has been confirmed.42 In the present study, G12D mutations were observed in 54% of patients with gastric cancer and in 35% of patients with colorectal cancer among ctDNA samples. Here, EGFR is linked to colorectal cancer.